Immunology
Beyond capital -- what it takes for biopharma startups to succeed
Investors are more interested in the biopharmaceutical sector than ever before. But success for biopharma startups means more than just securing investment funds -- it requires successful product commercialization. A panel of biopharmaceutical and finance executives discussed the factors that go into ensuring success on January 12 at the Biotech Showcase virtual event.  Discuss
What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event.  Discuss
Are biotech companies really high-risk investments?
Despite the public perception of the biotech industry as a high-risk investment, a new analysis published in PLOS One on January 6 found that over the long term, biotech firms that went public performed just as well as nonbiotech companies by various measures of financial success.  Discuss
Top Operation Warp Speed official shares lessons learned from COVID-19
The global COVID-19 pandemic has placed an urgent burden on governments to serve society, and with the help of the biotechnology and pharmaceutical industries, the job is getting done. That's according to Moncef Slaoui, PhD, chief adviser of the U.S. government's Operation Warp Speed project, who discussed his unique experiences at an advance session of the Biotech Showcase virtual event on January 5.  Discuss
COVID-19 to have long-lasting effect on biotech industry
The COVID-19 pandemic will have a widespread and long-lasting effect on the biotechnology industry, according to speakers at a January 5 presentation held in advance of the Biotech Showcase virtual event taking place January 11-15. Biotech companies have pivoted on a massive scale to pursue infectious disease research -- and not all of them will be successful.  Discuss
Allergic reactions to COVID-19 vaccines shouldn't stop vaccinations
COVID-19 vaccines currently approved for emergency use by the U.S. Food and Drug Administration are safe even among people with food or medication allergies, according to allergists from Massachusetts General Hospital. A review of all relevant information was published in the Journal of Allergy and Clinical Immunology: In Practice on December 31.  Discuss
Top 10 ScienceBoard stories for 2020
For many of us, 2020 did not pan out as planned. The emergence of the COVID-19 pandemic has drastically changed our daily lives. Here at ScienceBoard.net, we have provided timely and evidence-based information to our readers regarding COVID-19, as well as many other topics in the biopharmaceutical and life sciences industries.  Discuss
FDA issues EUA for Moderna COVID-19 vaccine
Just one day after a favorable committee recommendation, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the messenger RNA (mRNA) COVID-19 vaccine from Moderna. The company's mRNA-1273 vaccine now becomes the second COVID-19 vaccine on the U.S. market, after a vaccine from Pfizer and BioNTech was granted an EUA last week.  Discuss
FDA committee votes favorably for Moderna COVID-19 vaccine EUA
Moderna's messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, received a favorable recommendation on December 17 from an advisory committee to the U.S. Food and Drug Administration (FDA). The committee's OK means that mRNA-1273 will probably receive an emergency use authorization (EUA) within days.  Discuss
New immunotherapy piggybacks off polio vaccine to treat cancer
As if we needed another reason to get vaccinated, researchers have developed a technology that leverages the polio vaccine to help treat cancer for those who develop the disease later in life. The technology, conceived at Duke University and developed by Istari Oncology, uses antigens produced by the polio vaccine to trigger the immune system to eat away at targeted cancer cells.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter